

Cumulative Index 1990

Volume 6

February	UROLOGIC CARE IN THE ELDERLY , pages 1-227
May	CLINICAL PHARMACOLOGY , pages 229-457
August	PERIOPERATIVE CARE OF THE OLDER PATIENT , pages 459-691
November	DIABETES MELLITUS IN THE ELDERLY , pages 693-991

Note: Page numbers of issue and article titles appear in boldface type.

Abdomen, examination of, in urinary dysfunction, 34

Abdominal aortic aneurysm, repair of, renal failure in, 562

Abdominal surgery, 589-607
and sexual dysfunction, 192
functional residual capacity following, 677
postoperative complications of, 589-590
timing of, 589

Abdominal wall, hernia of, surgery for, 601
reconstruction of, plastic surgery for, 646, 648

Absorption, of drugs, in perioperative patient, 543-544

Acetohexamide, for diabetes mellitus, initial doses of, 912
properties of, 905-906

Acetophenazine, for dementia, review of literature on, 414

Acid-base disorders, in surgical patient, 563-564

Activities of daily living, limitations in, age-specific rates for, 3

Acute abdomen, atypical/nonspecific presentation of, 726

Acute ischemic optic neuropathy, 665

Acute renal failure. *See Renal failure, acute.*

Acute tubular necrosis, perioperative risk of, 564
postoperative, 566

Adhesions, small bowel, surgery for, 599

Adrenergic agents, and urinary retention, 61

Adrenergic function, changes in, in healthy elderly, 287
in hypertensive elderly, 288

Adrenergic sensitivity, alterations in, 272

Adverse drug reaction, definition of, 295

Affective disorders, in diabetics, 731-746

Age profile, in United States population, 3-4

Aging. *See also Elderly.*
and female sexuality, 198
and glucose intolerance, 850-853
effect on health, 860
cardiac physiology and, 511-512
cognitive changes with, 732-733
of United States population, and health care financing, 959

Agitation, postoperative, 544-546
psychopharmacologic management of, 546-549

Airway, in surgical patient, evaluation for anesthesia, 499-500

Akathisia, with neuroleptics, 412

Alcohol-related problem, with drug ingestion, definition of, 295

Alcohol use, and sexual dysfunction, 192

Alcohol withdrawal syndrome, perioperative, 548

Aldose reductase inhibitors, for diabetes-related impotence, 787

Alfentanil, with local anesthesia,¹ 87

Allopurinol, for renal calculus disease, 127

Alpha-adrenergic blockade, for benign prostatic hypertrophy, 73-75

Alpha-blockers, postsynaptic, for hypertension, 339

Alternate drugs, 423-444

Ambulatory surgery, preoperative evaluation for, 494-495
procedural considerations in, 495-497

American Society of Anesthesiologists Physical Status Scale, 471

Aminoglutethimide, for benign prostatic hyperplasia, 625

Amitriptyline, for perioperative depression, 551

Ammonium trapping, in renal tubular acidosis, 21-22

Amputation, in diabetics, for bone infection, 760-761
home management following, 955

Amputees, rehabilitation of, 680-681

Analgesics, 345-364
adjuvant, 357-359
narcotic, 350-357
nonnarcotic, 349-350

Anatomy, in surgical patient, evaluation for anesthesia, 499-502

Androgen, action of, in human prostate, mechanism of, 626
blockade of, for metastatic prostate cancer, 150
deprivation of, for benign prostatic hyperplasia (hypertrophy), 75-77, 625

Anesthesia, 499-510
altered sensitivity to, 278, 503-504
in ambulatory surgery, 496
in cardiovascular disease patient, 516-517
inhaled, 503
local, surgery using, 85-99, 504
risk of, evaluation of, 504-505
in surgery, 463

technique of, in geriatric patient, 506-507

Angina, in surgical patient, 517

Angiotensin converting enzyme inhibitors, altered sensitivity to, 276
for hypertension, 341, 430
in prevention of diabetic nephropathy, 820

Antidiuretic drugs, for hypertension, 338-339

Antiarthritis, 435-437

Antibiotics, for bone infections, in diabetes mellitus, 760
in renal calculus disease, 126

Anticholinergic effects, with neuroleptics, 548

Anticholinergics, and urinary retention, 61
for bladder hyperreflexia, 62
for bladder instability, 63
for bronchodilation, 426-427
for urinary incontinence, 64

Anticoagulation, altered response to, 279-280

problems with, in surgical patient, 539-540

Anticonvulsants, 358

Antidepressants, 399-410
and electrocardiogram, 407
cyclic, selection of, 402-405
side effect profile of, 404-405
disposition of, altered, 402
perioperative use of, 550
prior response to, history of, 402
types of, 402

Antiemetics, altered sensitivity to, 278-279

Antihypertensives, and diabetes-related impotence, 778-779
and sexual dysfunction, 190
therapy with, 335-344
alternate drugs for, 429-431
annual cost of, 430
investigation of, in quality-of-life assessment, 315

Antimicrobial therapy, for foot infections, in diabetics, 754-755

Antipsychotics, 411-422

Anxiety, diabetes-related, 879
perioperative, differential diagnosis of, 552
psychopharmacologic management of, 551-553
sedatives for, 359

Aortic insufficiency, in surgical patient, 519-520

Aortic stenosis, in high-risk elderly, alternatives to surgery for, 488
in surgical patient, 519
perioperative risk of, 515

Appendix, surgery on, 601-602

ARF. See *Renal failure, acute*.

Arrhythmia, perioperative, 523-525
with oculocardiac reflex, 660

Arthroplasty, for femoral neck fractures, 573, 577
hip, total, for osteoarthritis, 577-579

Atheroembolic disease, renal failure in, 562

Athletes, glucose tolerance in, 851-852, 855

Atrioventricular node function, impaired, in surgical patient, 523-524

Austin-Moore prosthesis, for femoral neck fracture, 576

Autonomic nervous system, age-prevalent disease of, 725
functional changes in, in healthy elderly, 287
in hypertensive elderly, 288
in normal micturition, 56
physiologic and homeostatic mechanisms in, 271-273

Autonomic neuropathy, in diabetics, home management of, 954

Azotemia, in acute renal failure, 25
in surgical illness, 561

Bacitracin, for pseudomembranous colitis, 429

Bacteriuria, and urolithiasis, 119
definition of, 44
in elderly, treatment of, 48
in urinary dysfunction, 35
in urinary tract infection, 44–45

Balanitis, erosive, 206

Barbiturates, surgical use of, in cardiovascular disease patient, 516

Baroreceptor function, alterations in, 272–273

Basal cell carcinoma, removal of, 638–639

Behavior, with depression, in diabetics, 738

Behavior modification, alternative drugs for, 432–433

Benign prostatic hyperplasia (hypertrophy), and urinary tract infection, 46–47
etiology of, 70–71
histologic prevalence of, 611
in high-risk elderly, alternatives to surgery for, 483, 487–488
incidence of, 69–70
indication for surgery, 73
management of, 69–84
pathology of, 71
pathophysiology of, 71
physical examination in, 72
symptoms of, 71–72
treatment of, 73–80
 indications for, 615–616
 nonoperative, 621–626
 pharmacologic therapy, 73–77, 624–626
 alpha-adrenergic blockade, 73–75
 androgen deprivation, 75–77
 surgical, 616–621
 preoperative management of, 617
 technique selection in, 617–618

Benzodiazepines, altered sensitivity to, 277–278
alternatives to, 434–435
for perioperative anxiety, 552–553
surgical use of, in cardiovascular disease patient, 516

Beta-adrenergic antagonists, pharmacokinetics of, 288

Beta₂-agonists, for bronchodilation, 426

Beta-blockers, altered sensitivity to, 274–275
 for hypertension, 337–338

Bicarbonate absorption, in renal tubular acidosis, 21

Biguanides, for diabetes mellitus, 699–700

Biliary stone disease, in high-risk elderly, alternatives to surgery for, 481–486

Biliary tract surgery, 593–595
 renal failure in, 562

Biochemical parameters, in elderly, 328

Biopsy instrument, for prostate biopsy, 138–139

Bisexuality, in older women, 200–201

Black race, in non-insulin-dependent diabetes mellitus, role in nephropathy, 819

Bladder, cancer of. See *Bladder cancer*.
hyperreflexia of, bladder outlet obstruction vs, 62

instability of, bladder outlet obstruction vs, 62

tumors of, small, resection of, local anesthesia for, 92–93

Bladder cancer, classification of, systems of, 175
in geriatric patients, 173–184
 chemotherapy for, intravesical, 180
 systemic, 179–180
 cystectomy for, radical, 174–176
 segmental, 176–177
 transurethral, 176–177
 photodynamic therapy of, 179
 radiation therapy of, alternatives in, 178–179
 external beam, 177–178

Bladder outlet obstruction, following transurethral resection of prostate, 81

Bleeding, and ocular risk, in eye surgery, 662

Blepharoplasty, in elderly, 656

Blindness, in diabetics, 829, 833

Blood pressure, and proliferative diabetic retinopathy, 835
control of, in prevention of diabetic nephropathy, 819–820

Blood urea nitrogen, increased, in acute renal failure, 560
with altered glomerular filtration rate, 17

Bone infections, of foot, in diabetics, 756–761

Bone pain, in prostate cancer, treatment of, 155

Bone scanning, for prostate cancer staging, 143

Bowen's disease, 216–217

Brain damage, with drug-induced hypoglycemia, 938

Breast, reconstructive surgery of, 652–655
 breast reduction, 653–654
 tissue expanders for, 655

Breast cancer, plastic surgery for, 647
 primary, in high-risk elderly, alternatives to surgery for, 483, 489

Bronchodilators, alternative, 425–428
 combinations of, 427
 ease of administration of, 427
 quality of life with, 428

Bulbocavernosal electromyography, in diabetes-related erectile dysfunction, 782

Bupivacaine, for local anesthesia, 88

Buserelin, for benign prostatic hyperplasia, 625

Buspirone, for behavior modification, 433
Butorphanol, 352

Cachexia, neuropathic, in diabetics, 697
Calcium, in diabetics, 887-888
 tubular reabsorption of, defective, 22-23
Calcium antagonists, altered sensitivity to,
 275-276
 pharmacokinetics of, 288-289
Calcium channel blockers, for hypertension,
 340
Calf stimulation, electrical, thromboembolism prophylaxis with, 536
Candidiasis, urologic, 207
Carbohydrate, dietary, in diabetics, 892
Carcinoma, basal cell, removal of, 638-639
 squamous cell, of head and neck, plastic
 surgery for, 642
Cardiac activity, postoperative, effect on discharge, 677
Cardiac function, changes in, with aging and hypertension, 286
Cardiac pacemaker, indications for, in surgical patient, 524
Cardiac physiology, and aging, 511-512
Cardiac risk, assessment of, 512-516
Cardiovascular disease, in diabetics, 714-715, 908, 927, 935-936
 in high-risk elderly, alternatives to surgery for, 483, 488
 noncardiac surgery in, 511-529
Cardiovascular drugs, altered pharmacodynamics and pharmacokinetics of, 285-292
 altered sensitivity to, 274-276
Cardiovascular effects, of sulfonylureas, 908
Cardiovascular system, age-prevalent disease of, 725
 age-related physiologic changes in, 723
 pharmacodynamics of, relation to pharmacokinetics in aging, 288-289
 structural changes in, with aging and hypertension, 286-287
Cataracts, in diabetics, 831
 removal of, anesthetic problems in, 507-508
 risk with, 662
Catheter, condom, for urinary incontinence, 64, 110
 indwelling, for urinary incontinence, 110-111
Central nervous system, age-prevalent disease of, 725
 age-related physiologic changes in, 723
 altered drug response of, 276-279
 response to antidepressants, 401
Cephalexin, for foot infections, in diabetics, 754
Cerebrovascular accidents, in diabetics, 937
 urinary dysfunction following, 57-60
 urologic effects and management of, 55-68
Chemical dissolution, for biliary stone disease, in high-risk elderly, 484-485
Chemotherapy, for hormone-resistant metastatic prostate cancer, combined, 152-153
 cytotoxic, 150
 single-agent, 151
Chest wall, reconstruction of, plastic surgery for, 646
Chlorpromazine, for dementia, review of literature on, 414
Chloropropamide, for older diabetics, 914-915
 initial doses of, 912
 properties of, 905-906
Cholangitis, surgery for, 594-595
Cholecystitis, acute, surgery for, 593-594
Cholecystojejunostomy, for pancreatic carcinoma, 598
Cholecystostomy, for seriously ill patient, 594
Cholestatic jaundice, with sulfonylureas, 907
Cholestyramine, for pseudomembranous colitis, 429
Cholinergic sensitivity, alterations in, 272
Chorioretinitis, with AIDS, 665
Chromium, in diabetics, 698, 886
Chronic disease, in elderly United States population, prevalence of, 704
Cimetidine, pharmacokinetics of, clinical example of, 264
Clamps, for urinary incontinence, 110
Clean intermittent self-catheterization. See *Intermittent self-catheterization*
Clearance, drug, definition of, 257-258
Clindamycin, for foot infections, in diabetics, 754
Clinical pharmacology, geriatric, 229-234
Clonidine, and sexual dysfunction, 190
 for hypertension, 338
Clotrimazole, for diabetic foot lesions, 763
Codeine, 352
Cognitive changes, with aging, 732-733
Cognitive disorders, in elderly diabetics, 727, 731-746, 868, 878-879
Coitus, in older women, frequency of, 199-200
Colitis, pseudomembranous, drug-induced, 428-429
Colon volvulus, in high-risk elderly, alternatives to surgery for, 482, 486
 surgery for, 602-603
Coma, with drug-induced hypoglycemia, 938
Combination therapy, for hypertension, 341
Compliance, definition of, 445-446

in elderly, 445–452
 assessment of, 448
 prescribing for, 450–451
 problem with, dealing with, 448–449
 improved therapeutic methods in, 449–450
 magnitude of, 446–448
 Complications, in surgical treatment, decision-making in, 477–478
 prevention of, 476–477
 Computed tomography, for prostate cancer staging, 141
 Concentrating mechanism, defective, with impaired tubular function, 24–25
 Condom catheter, for urinary incontinence, 64, 110
 Conduction abnormalities, in surgical patient, 523–525
 Congestive heart failure, atypical/nonspecific presentation of, 726
 in surgical patient, 521–522
 Conjunctivitis, with uveitis, 665
 Consciousness, alterations of, in diabetic hyperosmolar state, 801
 Constipation, postoperative, effect on discharge, 678
 Copper, serum, in diabetics, 886–887
 Coronary artery disease, and sexual dysfunction, 188
 Coronary artery revascularization, history of, in surgical patient, 518
 Corpus cavernosal electromyography, in diabetes-related erectile dysfunction, 782
 Cortisol, altered sensitivity to, 280
 Cosmetic surgery, for elderly, 655–656
 Cough, and ocular risk, in eye surgery, 662
 Creatine clearance, decrease in, with altered glomerular filtration rate, 15
 Creatinine, clearance rate of, calculation of, 558
 increased, in acute renal failure, 560
 with altered glomerular filtration rate, 16–17
 reabsorption of, with urinary tract replacement, 18
 Cyclic antidepressants, selection of, 402–405
 Cyproterone acetate, for benign prostatic hyperplasia, 625
 Cystectomy, for bladder cancer, in geriatric patients, 174–177
 alternatives to, 181
 Cystometry, in urinary dysfunction, 36–37
 Cystoscopy, for urinary tract dysfunction, 39, 111
 local anesthesia for, 91–92
 Cystourethroscopy, in prostate evaluation, 614–615
 Cytotoxic chemotherapy, for metastatic prostate cancer, 150
 Dakin's solution, for diabetic foot lesions, 762
 Dark field examination, for syphilis, 208–209
 Death, premature, in diabetics, 714–716
 with drug-induced hypoglycemia, 938
 Decision-making, in surgical intervention, ethical, 461
 initial, 460–461
 medical, 462
 with complications, 477–478
 Decubitus ulcers, in diabetics, home care of, 949–951
 Deep vein thrombosis, etiology of, 531–532
 in hip surgery, 580
 postoperative, risk of, 533
 prophylaxis for, in surgical patient, 531–542
 modalities of, 533–536
 risk factor assessment in, 532–533
 Dehydration, and diabetic hyperosmolar state, 798–799
 Delirium, etiologic categories of, 545
 in hip surgery, 581
 laboratory evaluation of, 546
 postoperative, 544–546
 therapeutic drugs associated with, 547
 Dementia, behavioral and psychotic symptoms of, 413
 laboratory evaluation of, 546
 neuroleptics for, adverse effects of, 416–417
 guidelines for, 419–420
 review of literature on, 413–418
 postoperative, 544–546
 preneuroleptic evaluation of, 419
 psychosocial therapies for, 420–421
 treatable causes of, 727
 Demographic changes, financial implications of, 1–12
 Dental caries, disabilities related to, 331
 Depression, atypical/nonspecific presentation of, 726
 characteristics of, 399–400
 in cardiovascular disease, treatment of, 407
 in dementia, treatment of, 408
 in diabetics, 738–741
 perioperative, psychopharmacologic management of, 549–551
 pretreatment evaluation of, 406
 primary, etiology of, 400
 psychotic, 408
 secondary, drug-induced, 401
 illness-induced, 402
 treatment-resistant, 408
 Dermatitis, erosive, Paget's disease vs, 218
 urologic, 206–207
 Dermatologic disorders, in diabetics, 698
 Dermatologic effects, of sulfonylureas, 907

Dermatology, urologic, 205-219

DES, for metastatic prostate cancer, 149

Desipramine, side effects with, 404

Desmopressin, for urinary incontinence, 64

Detrusor dysfunction, following cerebrovascular accidents, 58-59

Dextran 40/70, thromboembolism prophylaxis with, 535

Diabetes mellitus, and sexual dysfunction, 189

- disabilities related to, 331
- in eye surgery, 663
- non-insulin-dependent, adequate test for, 842
- age-specific incidence of, 708
- as great masquerader, 724-728
- atypical presentation of, 721-729
- characteristics of, 710
- clinical type of, definition of, 810-811
- cognitive and affective disorders in, 731-746
- complications of, 714-715, 933
- home management of, 953-955
- hospital utilization with, 964-965
- data flow sheet for, for office chart, 876-877
- definition of, 841
- depression with, 738-741
- development of, age-related factors in, 856-857
- economic impact of, 959-970
- epidemiology of, 703-719
- functional problems with, 875-880
- health care utilization in, 960-966
- hospital costs of, 962-965
- impact on society, 841-842
- in nursing home patients, 700
- laboratory use associated with, 967-968
- management of, 699-700
- medical care for, 709-714
- by office-based physician, 710-712
- hospitalization for, 712-713
- type of therapy for, 709
- mortality from, 716-718
- nephropathy in, risk factors for, 818-819
- nutritional factors in, 698-699
- ocular problems in, 827-837
- pathophysiology of, 923-924
- pharmacy use associated with, 967-968
- physician visits associated with, 711-712, 966-968
- physiologic and psychosocial effects of, 733
- prevalence and incidence of, 703-709
- progression of, 843-844
- psychological factors in, 696-697
- renal complications in, 807-825
- screening for, 839-848
- consequences of, 845-846
- criteria for, 839-840
- special syndromes in, 697-698
- sulfonylurea agents for, 911
- therapy for, 844-845
- choice of, 926-928
- rationale for, 924-926
- reasons for, 695-696
- undiagnosed, estimated prevalence of, 707-709
- unique aspects of, 693-702

Diabetes Quality-of-Life Measure, 869, 874

Diabetic hyperosmolar state, 797-806

- clinical presentation of, 801-802
- epidemiology of, 799-801
- laboratory tests for, 802
- management of, 802-803
- mortality in, 803-804
- pathophysiology of, 798-799
- prevention of, 804-805
- prognosis in, 803-804

Diabetic nephropathy, clinical and public health impact of, 807-808

- increased prevalence of, with poor glycemic control, 935
- pathology of, 811-818
- prevention of, 819-821
- risk factors for, 818-819

Diabetic neuropathy, increased prevalence of, with poor glycemic control, 935

Diabetic patients, agency referral of, 951-952

- dietary management in, 883-901
- expenditures for, 965
- functional status measurement in, 865-882
- glycemic control in, 933-941
- home assessment of, 868-875
- home care of, 943-957
- insulin treatment in, 923-931
- male sexual response in, 772-773
- nutritional status in, 883-901
- sulfonylureas for, 903-921
- insulin with, 915-917
- treatment goals for, 917

Diabetic retinopathy, 828-829

- incidence of, 834-835
- increased prevalence of, with poor glycemic control, 935
- severity of, 830

Diagnostic testing, effect on surgical outcome, 462

Diet, for diabetes mellitus, 709, 844, 883-901, 926

- optimal, 892-895
- in renal calculus disease, 127

Diet-related diseases, management and prevention of, 330-331

Dietitian, in home health care team, 944

Diffusional, 385-386

Digoxin, altered sensitivity to, 276

and impotence, 188
 Diltiazem, for hypertension, 340
 Dilutional hyponatremia, with transurethral resection of prostate, 619
 Discharge assessment form, 671
 Discharge planning, for surgical patient, 669-683

- assessment of needs, 675
- communication of, 676-677
- definition of, 669
- discharge criteria for, 673
- financial coverage, 675-676
- goals of, 669
- initiation of, 671
- legal aspects of, 670
- medical/nursing needs in, 670
- need for, 670-671
- organization of, 670
- patient/family involvement in, 671-672
- practical aspects of, 673-677
- return appointments, 676
- timing of discharge, 673

 Discharge summary form, 674
 Disease, age-prevalent, 722, 725

- atypical/nonspecific presentation of, 722-724, 726
- normal aging vs., 722

 Distribution, of drugs, in perioperative patient, 543

- volume of, definition of, 258

 Disulfiram-like reaction, with sulfonylureas, 907
 Diuretics, altered sensitivity to, 276

- and diabetes-related impotence, 778-779
- for hypertension, 336-337
- investigation of, in quality-of-life assessment, 313-314

 Diverticular disease, surgery for, 602
 Dopamine, altered sensitivity to, 279
 Dopamine antagonists, altered sensitivity to, 279
 Driving, functional problems with, in elderly diabetics, 877
 Drug(s), absorption of, 258-259

- adverse reactions to, 293-307
 - avoidance of, 302-304
 - definitions of, 293-296
 - drugs most frequently involved in, 302
 - frequency of, 296-297
 - operational assessment of, 295-296
 - patient reporting of, 300-301
 - reasons for, 297-301
- alternate, 423-444
- clearance of, definition of, 257-258
- concentration of, measurement of, 270
- distribution of, 259
- elimination half-life of, definition of, 258
- ideal, characteristics of, 423-425
- interactions of, evaluation of, 303

 investigation of, in quality-of-life assessment, 312-315

- metabolism of, 260-261
- renal excretion of, 261-262
- sensitivity to, alterations in, 274-280
- testing of, and adverse drug reactions, 298-299

 therapeutic concentration range of, 263
 toxicity of, causes of, 301
 volume of distribution of, definition of, 258
 Drug treatment, and quality of life, in elderly, 309-317

- compliance with, in elderly, 445-452
- outcome objects in, 450-451

 Drug trials, clinical, 235-255

- age effect in, 246
- data analysis in, 247-249
- design of, 242-244
- dose in, 246
- duration of, 244-245
- endpoints in, 246-247
- evaluation of, 249-250
- future of, 236-237
- goals in, 242-243
- patient parameters in, 240-242
- pharmacologic data in, 245-246
- placebo use in, 244
- quality checkpoints for, 238
- randomized, problems with, 237
- risk/benefit ratio in, 239-240
- safety of, 239-242
- trial drug for, 245-246
- types of, 243-244

 Drug use, information needed in, 236

- multiple, and adverse drug reactions, 301

 Duodenum, surgery on, 590-593
 Dyspareunia, in older women, 200
 Ears, age-prevalent disease of, 725

- age-related physiologic changes in, 724

 Economic impact, of diabetes mellitus, 877-878, 959-970
 Ejaculation, changes in, with aging, 186-187

- in diabetes, 772-773

 Elastic stockings, gradient, thromboembolism prophylaxis with, 536-537
 Elderly, altered pharmacodynamics in, 269-283

- altered pharmacokinetics in, 257-267
- analgesics in, 345-364
- antihypertensive therapy in, 335-344
- bladder cancer in, 173-184
- cardiovascular drugs for, altered pharmacodynamics and pharmacokinetics in, 285-292
- clinical drug trials in, 235-255. See also *Drug trials*.

Elderly (Continued)

- clinical research in, 229
- compliance in, 445–452
- definition of, 841
- depression in, characteristics of, 399–400
- diabetes in, non-insulin-dependent, 693–970
- drug use in, 233
- energy requirements of, 322–324
- health status of, 6–7
- height-weight tables for, 327
- history in, physical examination vs, 463
- hypertensive, cardiovascular changes in, 288
- impaired nutrition in, factors associated with, 884
- impotence in, diabetes-related, 771–795
- nutritional requirements of, 322–324
- nutritional status in, assessment of, 323–326
- physiologic and homeostatic mechanisms in, 271–274
- sexual dysfunction in, females, 197–203
males, 185–196
- urologic dermatology in, 205–219

Electrocardiogram, antidepressants and, 407

Electroconvulsive therapy, for perioperative depression, 551

Electrolyte(s), disorders of, in surgical patient, prevention and management of, 564–567
perioperative management of, 557–569

Electrolyte balance, in eye surgery, 663
postoperative support of, 566–567

Electromyography, in urinary dysfunction, 38

Elimination half-life, definition of, 258

Emotional function, limitations of, in elderly diabetics, 867–868, 873

End-organ abnormalities, and diabetes-related impotence, 776–777

End-stage renal disease, diabetic nephropathy and, 807–808, 810

Endocrine abnormalities, and diabetes-related impotence, 777–778

Endocrine system, age-prevalent disease of, 725
age-related physiologic changes in, 723, 773

Endoscopic sphincterotomy, for biliary stone disease, in high-risk elderly, 484

Endoscopy, local anesthesia for, 91–94
percutaneous, for urolithiasis, 123–125

Endourodynamics, in urinary dysfunction, 39–40

Endourologic management, of lower urinary tract dysfunction, 109–113

Enzyme sensitivity, alterations in, 273–274

Epidermoid carcinoma, of penis, 215

Erectile dysfunction, diabetes-related, diagnostic testing in, 780–784

physiologic causes of, 772

Ethnic origin, in United States population, 4

Excitation, sexual, in male diabetics, 772–773

Exercise, aerobic, effect on glucose tolerance, 857–860
effect on insulin sensitivity, 857–860
for diabetics, 699, 845

Extrapyramidal effects, with neuroleptics, 412, 548

Extremities, plastic surgery of, 645–652

Eye(s), age-prevalent disease of, 725
age-related physiologic changes in, 724
diabetes-related problems in, 827–837

Eye disease, systemic illness and, 665–666

Eye drops, systemic absorption of, 664

Eye patients, medical problems in, 663–666

Eye surgery, in elderly, 659–667
mortality in, 660
risk assessment in, 659–663
medical risks, 659–662
ocular risks, 662–663

Facelift, in elderly, 656

Fat, dietary, in diabetics, 892–893

Femoral neck fracture, pathogenesis of, 572
surgical procedures for, 572–574

Fentanyl, with local anesthesia, 87

Fiber, dietary, in diabetics, 893

Fitness, management of, 331

Flap, skin, definition of, 635–636

Fluid balance, in eye surgery, 663
perioperative management of, 557–569
postoperative support of, 566–567

Fluid intake, increased, for urolithiasis, 122

Fluid therapy, for diabetic hyperosmolar state, 802–803

Fluoroscopic management, of lower urinary tract dysfunction, 111–112

Flutamide, for benign prostatic hyperplasia, 625
for benign prostatic hypertrophy, 76

Folate, in diabetics, 890

Follow-up, in surgical patient, 466

Foot, home care of, for diabetics, 949
education in, 764–765

infections of, in diabetics, 747–769
approach to, algorithm for, 759
bacterial isolates from, 752–753
bone, 756–761
diagnosis of, 756–760
pathophysiology of, 756
treatment of, 760–761

clinical presentation of, 751–752
culture of, specimen collection for, 750–751

etiologic agents of, 750–751

treatment of, 753–756

- antimicrobial therapy, 754-755
- surgical treatment, 755-756
- lesions of, in diabetics, debridement of nonviable tissue in, 761-762
- dressings for, 763-764
- edema in, treatment of, 764
- epidemiology of, 747-748
- footwear for, 764
- local care of, 761-764
- pathophysiology of, 748-750
- topical regimens for, 763
- soft tissue reconstruction of, 652
- Forehead, basal cell carcinoma of, removal of, 639
- Free flap, definition of, 636
- Free water, clearance of, formula for, 24-25
- loss of, and diabetic hyperosmolar state, 798-799
- Fructosamine assay, in assessment of diabetic control, 694-695
- Full bladder syndrome, and hypertension, in eye surgery, 664
- Functional limitations, in diabetics, 865-882
- clinical implications of, 866-868
- common problems with, 875-880
- identification of, 868-875
- risk of, 866

- Gallbladder, carcinoma of, surgery for, 595
- Gastric cancer, surgery for, 592
- Gastric surgery, syndromes after, 592
- Gastric volvulus, surgery for, 592-593
- Gastroenterostomy, for pancreatic carcinoma, 598
- Gastrointestinal effects, of sulfonylureas, 907
- Gastrointestinal toxicity, with nonsteroidal anti-inflammatory drugs, 436
- Gastrointestinal tract, age-prevalent disease of, 725
- age-related physiologic changes in, 723
- Gastroparesis, in diabetics, home management of, 954
- Gastrostomy, feeding, 592
- General surgery, thromboembolism prophylaxis in, 539
- Genital area, dermatitis in, erosive, 206
- Genitourinary tract, age-prevalent disease of, 725
- dysfunction in, in elderly, assessment of, 31-41
- function of, evaluation of, 32-39
- cystometry, 36-37
- electromyography, 38
- endourodynamics, 39-40
- flexible cystoscopy, 39
- history, 32-34
- laboratory studies, 35
- physical examination, 34-35

- urethral profilometry, 37-38
- urodynamics, 35-36
- uroflowmetry, 36
- videourodynamics, 38-39
- hemispheric specialization of, 65
- Gentamicin, pharmacokinetics of, 264-265
- Geographic distribution, in United States population, 4-5
- Geriatric. See also *Elderly*.
- Geriatric clinical pharmacology, 229-234
- Geriatric nutrition, 319-334
- Geriatrician, perioperative responsibilities of, 459-467
- Glaucoma, in diabetics, 832
- Glenohumeral joint, painful limitation of, in diabetics, 697
- Glipizide, for diabetes mellitus, initial doses of, 912
- properties of, 905-906
- Glomerular filtration rate, changes with aging, 15-18, 557-558
- Glomerulosclerosis, and diabetic nephropathy, 811-812
- hemodynamic factors in, 19
- Glucose, metabolic clearance rate of, 856
- Glucose control, in non-insulin-dependent diabetes mellitus, 933-941
- prevention of complications by, 925
- self-regulatory efforts at, and memory performance, 740
- with depression, 739-741
- Glucose intolerance, age-related, effect of physical activity on, 849-863
- and aging, 850-853
- effect on health, 860
- estimated prevalence of, 707-709
- Glucose tolerance test, oral, effect of physical training on, 858-859
- for non-insulin-dependent diabetes mellitus, 842-843
- Glyburide, for diabetes mellitus, initial doses of, 912
- properties of, 905-906
- Glycemic control, in elderly diabetics, 933-941
- Glycosylated hemoglobin, in assessment of diabetic control, 694-695, 843
- Goldman index, of cardiac reserve, 465
- Grief responses, in elderly diabetics, 879
- Groin, draining sinus of, plastic surgery for, 649
- Guanethidine, and sexual dysfunction, 191
- Gynecologic surgery, thromboembolism prophylaxis in, 538-539

- Haloperidol, for dementia, review of literature on, 414-415
- for postoperative agitation, 546

Head and neck, plastic surgery in, 637-645
 Health care, for diabetics, cost of, 961-968
 in United States, costs of, 1980-2040, 10
 financing of, 959
 utilization of, 7-8
 Height-weight tables, 327
 Hematologic system, age-prevalent disease of, 725
 parameters of, 328
 Hematuria, as indication for prostatectomy, 616
 history of, 34
 in urolithiasis, 120
 Hemiplegia, results of, left, 66
 right, 65
 Hemoglobin, glycosylated, in assessment of diabetic control, 694-695, 843
 Hemorrhage, with radical prostatectomy, 144
 Heparin, thromboembolism prophylaxis with, 533-534
 Hepatic metabolism, of drugs, in perioperative patient, 544
 Hernia, small bowel, surgery for, 599
 Herpes simplex, 209-210
 Hip, fracture of, nonoperative treatment of, 575-576
 pathogenesis of, 571-572
 preoperative patient status in, effect on rehabilitation, 583
 prospective payment for, impact of, 583-584
 prosthesis for, loosening of, 578
 surgery on, 571-587
 anesthetic problems in, 508
 perioperative complications in, 580-582
 preoperative evaluation for, 579-580
 rehabilitation in, 582-583
 Home health aide, in home health care team, 944
 Home (health) care, definition of, 944
 for diabetics, 943-957
 aspects of care provided, 948-953
 physician role in, 945-948
 selection of agency for, 947-948
 team approach to, 944-948
 for postoperative patient, 681
 Home intravenous antibiotic therapy, of infections, in diabetics, 952-953
 Homemaker, in home health care team, 944
 Homeostatic mechanisms, alterations in, 273
 Homosexuality, in older women, 200-201
 Hormone status, and urinary tract infection, 46
 in diabetes-related erectile dysfunction, 780
 Hormone therapy, with chemotherapy, for hormone-resistant metastatic prostate cancer, 153
 Hospital care, age-specific rates for, 3
 for diabetics, cost of, 962-965
 House calls, physician, for diabetics, 946
 Hunger, causes of, 330
 indices of, 332
 Hydrocelectomy, local anesthesia for, 96-97
 Hydrogen ion excretion, changes with aging, 559-560
 Hydromorphone, 351-352
 for postoperative agitation, 547
 Hydroureronephrosis, bilateral, as indication for prostatectomy, 616
 Hydroxyprogesterone caproate, for benign prostatic hyperplasia, 625
 Hypercalcuria, systemic conditions in, 116
 Hyperglycemia, and diabetic complications, 937-938
 chronic, and responses to bacterial infection, 748
 complications of, 695
 of aging, pathogenesis of, 693-694
 Hyperinsulinemia, with insulin therapy, for non-insulin-dependent diabetes mellitus, 927
 Hyperkalemia, in surgical patient, 563
 Hyperlipidemia, in diabetics, 699
 Hypernatremia, in surgical patient, 562-563
 Hyperosmolar state, diabetic, 797-806
 Hyperparathyroidism, primary, and urolithiasis, 117
 in high-risk elderly, alternatives to surgery for, 483, 489
 Hypertension, and proliferative diabetic retinopathy, 835
 and sexual dysfunction, 189-190
 disabilities related to, 331
 in eye surgery, 664
 ocular risk with, 662-663
 in non-insulin-dependent diabetes mellitus, control of, 934
 role in nephropathy, 818
 in renal artery stenosis, 15
 in surgical patient, 525-526
 pathophysiology of, 335-336
 treatment of, quality of life in, 314
 Hyperthyroidism, atypical/nonspecific presentation of, 726
 Hypertrophic obstructive cardiomyopathy, in surgical patient, 520
 Hyperuricosuria, and urolithiasis, 118
 Hypnotics, alternatives to, 434-435
 Hypoglycemia, drug-induced, adverse consequences of, 938
 with insulin therapy, 927
 with sulfonylureas, 909-910
 Hypoglycemics, oral, alternate drugs for, 431-432
 cost of, 432
 for non-insulin-dependent diabetes mellitus, 699, 709, 845
 Hypokalemia, in surgical patient, 563

Hyponatremia, dilutional, with transurethral resection of prostate, 619
in surgical patient, 562–563

Hypothermia, in diabetics, 698

Hypothyroidism, atypical/nonspecific presentation of, 726

Hypovolemia, in diabetic hyperosmolar state, 801

Ibuprofen, 387–388

Ideal drug, characteristics of, 423–425

Illness, acute, effect on surgical outcome, 462

Immobilization, and urolithiasis, 117

Impotence, diabetes-related, 771–795
end-organ abnormalities and, 777
endocrine abnormalities and, 777–778
evaluation of, 779–780
mechanism of, 775
medications and, 778–779
neurogenic abnormalities and, 776–777
organic factors in, 775
treatment of, 784–790
medical, 785–788
surgical, 788–789
vascular abnormalities and, 775–776
external vacuum tumescence devices for, 194
following transurethral resection of prostate, 81
medical causes of, 188–190
nonhormonal pharmacologic therapy for, 193–194
penile prosthesis for, 194, 789
vasoactive intracavernous pharmacotherapy for, 194
with radical prostatectomy, 145

Incontinence. See *Urinary incontinence*.

Induction agents, anesthetic, in geriatric patients, 502–503

Indwelling catheter, for urinary incontinence, 110–111

Infection(s), and ocular risk, in eye surgery, 663
in diabetics, 698
and diabetic hyperosmolar state, 799–800
and foot ulcers, 749
home care of, 952–953
urologic, 206–212
and urolithiasis, 118–119
culture of, 208
direct examination of, 207–208

Infective endocarditis, prophylaxis for, in surgical patient, 522

Information processing, in diabetics, 736

Infrapubic incision, for bilateral orchectomy, 95

Inguinal blockade, with local anesthesia, 90–91

Inguinal sinus, draining, plastic surgery for, 649

Insulin, action of, age-associated changes in, 853–856
animal studies of, 853–854
human studies of, 854–856
altered sensitivity to, 280
for diabetic hyperosmolar state, 802–803
for non-insulin-dependent diabetes mellitus, 700, 709, 923–931
sulfonylureas vs, 926–928
sulfonylureas with, 904, 915–917, 928

secretion of, age-associated changes in, 853–856
animal studies of, 853–854
human studies of, 854–856
sensitivity to, effect of exercise on, 857–860

Intercostal mononeuropathy, in diabetics, 697

Intermittent self-catheterization, 101–107
catheters for, 103
care of, 104
handling of, 106
for urinary incontinence, 64
history of, 102
patient evaluation in, 102–103
patient instruction in, 103–106
philosophy of, 102
schedule for, 104–105
supplies for, 105

Intertrochanteric fractures, surgical procedures for, 574–575

Intraabdominal abscess, in high-risk elderly, alternatives to surgery for, 482, 486

Intracavernous pharmacotherapy, vasoactive, for impotence, 194

Intraoperative management, in geriatric patients, 506

Intraoperative technique, in surgical treatment, 473–474

Inulin, reabsorption of, with urinary tract replacement, 18

Iron, in diabetics, 887

Ischemia, and foot ulcers, in diabetics, 749

Ischemic heart disease, in surgical patient, 517–519

Isolation, social, in elderly diabetics, 879

Isoxuprine hydrochloride, for diabetes-related impotence, 786–787

Jaundice, cholestatic, with sulfonylureas, 907

Jewett nail, for femoral neck fracture, 572–574

Job performance, functional problems with, in diabetics, 877

Kaposi's sarcoma, 217

Kegel's exercises, for stress incontinence, 63

Ketanserin, for benign prostatic hypertrophy, 75

Kidney(s). See also under *Renal*.

aging, pathophysiology of, 13-30

pharmacodynamics in, 27-29

physiologic changes in, 723

blood flow in, alterations in, 14-15

concentrating mechanism of, defective, 24-25

failure of, in non-insulin-dependent diabetes mellitus, 816-818

functional changes in, in non-insulin-dependent diabetes mellitus, 727

response to surgery, 560

Kidney stones. See *Urolithiasis*.

Knee prosthesis, plastic surgery with, 650

Knowles pinning, for femoral neck fracture, 572-573

Large intestine, surgery on, 602-603

Large vessel disease, in diabetics, 937

Learning, in non-insulin-dependent diabetes mellitus, 736

Leg, open fracture of, plastic surgery for, 651

pain in, in diabetics, 878

Lens implantation, risk with, 662

Leuprolide acetate, for benign prostatic hyperplasia, 625

Levorphanol, 352

LHRH agonists, for metastatic prostate cancer, 149

LHRH analogues, for benign prostatic hyperplasia, 625

Libido, in aging women, 198

in male diabetics, 772-773

Lichen planus, urologic, 212

Lichen sclerosus et atrophicus, urologic, 213-215

Lidocaine, for local anesthesia, 87-88

Life expectancy, in United States, 1-2
1990-2050, 3

Lip, plastic surgery of, for basal cell carcinoma, 638, 640

for granular cell myoblastoma, tissue expansion for, 641

for squamous cell carcinoma, 643

Lipid status, in diabetics, 884-885

Lithotripsy, for biliary stone disease, in high-risk elderly, 485-486

for urolithiasis, 122-125

mechanism of, 125

patient selection for, 126

Living arrangements, of United States population, 5-6

Local anesthesia, 85-99

agents for, 87-88

for bilateral orchectomy, 94-96

for hydrocelectomy, 96-97

for open surgical procedures, 94-98

for spermatocelectomy, 97-98

intraoperative sedation with, 86

nerve blocks with, 88-91

preparations and medications for, 86-88

transurethral injection of, sites for, 95

Lorazepam, for postoperative agitation, 546

Lower extremity, amputation of, in diabetics, 698

Lower urinary tract dysfunction, endourologic management of, 109-113

Loxapine, for dementia, review of literature on, 415

Luteinizing hormone-releasing hormone, for diabetes-related impotence, 786

Macular edema, in diabetics, 829-830

Magnesium, decreased, in diabetics, 698-699, 887

Magnetic resonance imaging, for prostate cancer staging, 141-142

of diabetic foot osteomyelitis, 758

Male sexual response, in diabetics, 772-773
normal age-related changes in, 773-774

Malignancy, atypical/nonspecific presentation of, 726

Malnutrition, causes of, 330

clinical signs of, 329

indices of, 332

risk factors for, 333

Manganese, serum, in diabetics, 887

Maracaine, for local anesthesia, 88

Marital status, of United States population, 5

Mastectomy, reconstructive surgery following, 652, 654

Masturbation, in older women, 200-201

Mediastinitis, following cardiac surgery, plastic surgery for, 645

Medical intervention, goals of, 459

Medication, and diabetes-related impotence, 778-779

Medication error, definition of, 296

Mege-trol acetate, for benign prostatic hyperplasia, 625

Memory, changes with aging, 732-733
in diabetics, 734-737

Men, elderly, sexual dysfunction in, 185-196

drug-induced, 190–192
in diabetics, 772–773
in hypertension, 189–190

Mentation, altered, in diabetics, 727

Meperidine, 352

Mesenteric ischemia, surgery for, 599–601

Metabolic assessment, in diabetes-related erectile dysfunction, 780

Metabolism, age-prevalent disease of, 725
alterations in, 273–274
age-related, 723

Metastatic cancer of prostate, 148–150. See also *Prostate cancer*.

Methyldopa, and sexual dysfunction, 190
for hypertension, 338

Metronidazole, for pseudomembranous colitis, 429

Microalbuminuria, in diabetics, 812–813

Micronutrients, in diabetics, 893–894

Micturition, normal, 56–57

Midazolam, with local anesthesia, 86

Minerals, in diabetics, 885–888, 894

Mitral regurgitation, in surgical patient, 520

Mitral stenosis, in surgical patient, 520

Monitoring, preoperative, 472–473

Monoamine oxidase inhibitors, and sexual dysfunction, 191
for depression, 406
perioperative, 551

Mood disorders, in elderly diabetics, 727

Morphine, 351

Mucosal bleeding, diffuse, surgery for, 592

Muscle relaxants, in geriatric patients, 503–504
surgical use of, in cardiovascular disease patient, 516

Muscle weakness, in diabetics, 697

Musculoskeletal system, age-prevalent disease of, 725
age-related physiologic changes in, 723

Myoinositol supplementation, for diabetes-related impotence, 787

Myocardial infarction, atypical/nonspecific presentation of, 726
following hip surgery, 582
in diabetics, 908, 927, 935, 937
perioperative risk of, 514
postoperative, effect on discharge, 679
recent history of, in surgical patient, 518
with drug-induced hypoglycemia, 938

Nafarelin, for benign prostatic hyperplasia, 625

Nalbuphine, 352

Naproxen, disposition of, 368

Narcotic(s), administration of, 353–354
altered sensitivity to, 278–279
analgesia with, 350–357
in geriatric patients, 504
physical dependence on, 355–356
prescribing of, guidelines for, 356–357
psychologic dependence on, 355–356
side effects of, 355
tolerance to, 355–356

Narcotic agonists, 351–352
equianalgesic doses of, 353

Narcotic agonists-antagonists, 352–353

Neck, desmoid tumor of, removal of, plastic surgery following, 643, 645

Neoplasms, colonic, surgery for, 603

Nephron(s), filtration rate in, reduction in,
effects of, 20
heterogeneity of, 20
reduction in, adaptation to, 18–21
underperfusion of, 15

Nephrostomy tract, creation of, for upper urinary tract transitional cell carcinoma, 165

Nephrotoxicity, with nonsteroidal anti-inflammatory drugs, 435

Nerve damage, with radical prostatectomy, 144–145

Neurogenic abnormalities, and diabetes-related impotence, 776–777

Neurogenic bladder, following cerebrovascular accidents, 58

Neuroleptics, 358–359
alternatives to, 433
anticholinergic effects of, 412
cardiovascular effects of, 412
concomitant medication with, 420
dosage and administration of, 419–420
follow-up and length of treatment with, 420

for dementia, adverse effects of, 416–417
guidelines for, 419–420
review of literature on, 413–418

for postoperative agitation, 546

for psychosis, 412
indications for, 419
side effects of, 412
management of, 420

Neurologic impairment, in diabetics, home management of, 954
with drug-induced hypoglycemia, 938

Neuropathic ulcers, plastic surgery for, 652

Neuropathy, following hip surgery, 582
in diabetics, and foot ulcers, 748
home management of, 954

Neurophysiologic evaluation, in diabetes-related erectile dysfunction, 781–782

Neurosurgery, thromboembolism in, prophylaxis for, 538

Neurotransmitters, of drugs, in perioperative patient, 544

Neurourologic examination, in urinary dysfunction, 34–35

Nipple reconstruction, following mastectomy, 654

Nitrazepam, effect on mental acuity, 278

Nitrendipine, for hypertension, 340

Nitroglycerine, for diabetes-related impotence, 786

Nocturia, history of, 33
in benign prostatic hypertrophy, 72

Noncompliance, intentional, definition of, 296

Nonnarcotic analgesics, 349–350

Nonprescription drugs, and sexual dysfunction, 192

Nonsteroidal anti-inflammatory drugs, 365–397

- absorption of, 366–367
- alternatives to, 436–437
- clearance of, 369
- disposition of, stereoselective, 370–371
- distribution of, 366–368
- drug interactions with, 375–380
 - effects on absorption, 375–376
 - effects on distribution, 376–377
 - effects on excretion, 378–379
 - effects on metabolism, 377–378
- pharmacodynamic, 379–380
- pharmacokinetic, 375–379
- efficacy of, 372
- excretion of, 371
- investigational, 389
- metabolism of, 368–370
- nonsalicylate, 386–389
- pharmacodynamics of, 372–375
- pharmacokinetics of, 366–372
- protein binding of, 367
- stereoisomers of, 370
- toxicity of, 372–375
 - gastrointestinal, 372–374
 - renal, 374–375
- unbound, pharmacokinetics of, 383

Normal aging, disease vs, 722

Nortriptyline, side effects of, 404

Norwegian scabies, 211–213

Nose, squamous cell carcinoma of, removal of, forehead flap for, 641

Nurse, in home health care team, 944

Nursing home care, for diabetics, cost of, 965–966

Nursing home patients, age-specific rates for, 3
urinary incontinence in, projected costs of, 11

Nutrition, geriatric, 319–334

Nutritional deficiencies, biochemical signs of, 329

Nutritional requirements, 322–324

- calculation of, 326–329
- changes in, variables determining, 325

Nutritional status, and adverse drug reactions, 301

assessment of, 323–326

in diabetics, 883–901

Obesity, control of, in diabetics, 934
management and prevention of, 331

Occupational therapist, in home health care team, 945

Ocular problems, in diabetics, 827–837

Oculocardiac reflex, arrhythmia with, 660

Omental flap, for mediastinitis, 645

Oncology, prostatic, 131–161

Open surgical procedures, local anesthesia for, 94–98

Operative mortality, in elderly, risk factors for, 472

Ophthalmic treatment, complications related to, 663–664

Opioids, for postoperative agitation, 547

Optic neuropathy, ischemic, acute, arteriosclerosis and, 665

Oral cavity, age-prevalent disease of, 725

- tumors of, plastic surgery for, 642–643

Oral glucose tolerance test, effect of physical training on, 858–859

- for non-insulin-dependent diabetes mellitus, 842–843

Orchiectomy, bilateral, local anesthesia for, 94–96

- for metastatic prostate cancer, 149

Organ systems, in anesthesia evaluation, 501–502

- major, surgical risk to, 464–465

Organic disorders, in male diabetics, and sexual dysfunction, 774–779

Orgasm, in male diabetics, 772–773

Orthopedic surgery, thromboembolism in, prophylaxis for, 536, 537

Osmolar clearance, formula for, 24

Osteoarthritis, hip surgery for, 576–579

Osteomyelitis, of diabetic foot, culture of, 758

- diagnostic tests for, 757

Osteoporosis, disabilities related to, 331

Oxalate, role in urolithiasis, 117, 128

Oxycodone, 352

Page's disease, 216, 218

Pain, acute vs chronic, 348–349

- assessment of, 345
- control of, nonpharmacologic methods of, 359–360
- mechanisms of, 346–348

Pancreas, surgery on, 595–598

- for carcinoma, 597–598

Pancreaticoduodenectomy, for pancreatic carcinoma, 597–598

Pancreatitis, acute, early prognostic signs of, 596
mortality of, 596
surgery for, 595-597

Papaverine, intracavernosal self-injection of, for diabetes-related impotence, 787-788

Parkinsonism, atypical/nonspecific presentation of, 726

Parotid gland tumor, removal of, facial nerve protection in, 642

Patient parameters, in clinical drug trials, 240-242

Patient-related risk, in surgery, 464

Pelvic lymphadenectomy, for prostate cancer staging, 142

Penile artery revascularization, for diabetes-related impotence, 788-789

Penile biothesiometry, in diabetes-related erectile dysfunction, 781

Penile erection, changes in, with aging, 186
physiology of, 772

Penile nerve block, with local anesthesia, 89-90

Penile prosthesis, for impotence, 194
diabetes-related, 789
for urinary incontinence management, 112
local anesthesia for, 97-98

Penile tumescence, nocturnal, testing of, in diabetes-related erectile dysfunction, 780-781

Penile vascular evaluation, in diabetes-related erectile dysfunction, 783-784

Penile venous ligation, for diabetes-related impotence, 789

Penis, carcinoma of, 215
dorsal nerve of, evaluation of, in diabetes-related erectile dysfunction, 781-782

Pentazocine, 352

Pentoxifylline, for diabetes-related impotence, 786

Peptic ulcer, surgery on, 590-591

Perinephric abscess, 50-51

Perioperative arrhythmias, 523-525

Perioperative drug therapy, 474-475

Perioperative responsibilities, of physician/geriatrician, 459-467
of surgeon, 469-480

Perioperative risk, in elderly, sources of, 460-466

Peripheral nerves, normal age-related physiologic changes in, 723

Peripheral neuropathy, with depression, in diabetics, 738

Peripheral vascular disease, in diabetics, 714
in high-risk elderly, alternatives to surgery with, 488-489
in surgical patient, 526-527

Personality change, in elderly diabetics, 727

Pharmacist, in home health care team, 945

Pharmacodynamics, alterations in, 269-283
in aging kidney, 27-29
in clinical drug trials, 245-246

Pharmacokinetics, altered, 257-267
clinical applications of, 262-265
in clinical drug trials, 245
terminology in, 257-258

Pharmacologic data, in clinical drug trials, 245

Pharmacologic erection programs, for diabetes-related impotence, 787-788

Pharmacologic therapy, for benign prostatic hypertrophy, 73-77
nonhormonal, for impotence, 193-194

Pharmacology, clinical, geriatric, 229-234
in geriatric patients, in anesthesia evaluation, 502-504

Pharmacotherapy, in perioperative patient, general principles of, 543-544

Phenothiazines, and sexual dysfunction, 191

Phenoxybenzamine, for benign prostatic hyperplasia, 625

Phentolamine stimulation test, in benign prostatic hypertrophy, 75

Phosphate, tubular reabsorption of, defective, 22-23

Physical activity, effect on age-related glucose intolerance, 849-863

Physical environment, assessment of, home health care in, 951-952

Physical examination, geriatric history vs, 463
in urinary dysfunction, 34-35

Physical function, in diabetics, evaluation of, 872
limitations of, 867

Physical health, and antidepressant selection, 403-404

Physical status, classification of, 471, 505
postoperative, effect on discharge, 679

Physical therapist, in home health care team, 945

Physician, in home health care team, 944
perioperative responsibilities of, 459-467
visits by, age-specific rates for, 3

Physiologic changes, age-related, normal, 723-724
postoperative, effect on discharge, 677-678

Piroxicam, 388-389

Placebo, for dementia, effects of, 418
in clinical drug trials, 244

Plantar ulcers, plastic surgery for, 653

Plastic surgery, in elderly, 633-657

Platelet inhibition therapy, in prevention of diabetic nephropathy, 821

Pneumatic compression, external, thromboembolism prophylaxis with, 535-536

Pneumonia, atypical/nonspecific presentation of, 726
following hip surgery, 582

Polydipsia, in diabetes mellitus, 727
 Polymedicine, and adverse drug reactions, 301
 Polymyalgia rheumatica, atypical/nonspecific presentation of, 726
 Polyphagia, in diabetes mellitus, 727
 Polyuria, in diabetes mellitus, 724
 Population growth, in United States, 1900–2030, 2
 Postanesthetic care, in geriatric patient, 508
 Postoperative care, in surgical treatment, 474
 Postoperative problems, persistent, effect on discharge, 678–679
 Postural hypotension, in diabetes mellitus, home management of, 954
 Potassium, disorders of, in surgical patient, 563
 excretion of, changes with aging, 559–560
 Prazosin, for benign prostatic hypertrophy, 74
 Preoperative evaluation, for ambulatory surgery, 494–495
 in geriatric patients, 505–506
 Preoperative preparation, 471–473
 effect on surgical outcome, 462
 Prescribing practices, and adverse drug reactions, 299–300
 Pressure ulcers, in diabetics, home care of, 949–951
 in hip surgery, 580–581
 prevention of, 476
 Procedural considerations, in ambulatory surgery, 495–497
 Propranolol, sensitivity to, relationship to aging, in hyperthyroid patients, 275
 Prostaglandin E-1, intracavernosal self-injection of, for diabetes-related impotence, 788
 Prostate, anatomy of, 610
 balloon dilation of, 623
 benign hyperplasia (hypertrophy) of. See *Benign prostatic hyperplasia (hypertrophy)*.
 biopsy of, 614–615
 cancer of, 131–161. See also *Prostate cancer*.
 disease of, epidemiology of, 609–611
 electrosection of, for benign prostatic hyperplasia, 619
 growth of, 609–611
 hyperplasia of, benign. See *Benign prostatic hyperplasia (hypertrophy)*.
 hyperthermic treatment of, for benign prostatic hypertrophy, 80
 hypertrophy of, benign. See *Benign prostatic hyperplasia (hypertrophy)*.
 laboratory studies of, 613
 oncology of, 131–161. See also *Prostate cancer*.
 physical examination of, 613
 radiologic evaluation of, 613–614
 spiral prosthesis for, 624
 stenting of, for benign prostatic hypertrophy, 80
 surgery of, 609–631
 patient evaluation for, 611–615
 transurethral balloon dilatation of, for benign prostatic hypertrophy, 78–80
 transurethral incision of, for benign prostatic hyperplasia, 620
 transurethral resection of. See *Transurethral resection of prostate*.
 Prostate cancer, 131–161
 clinical presentation of, 134–135
 diagnosis of, 136–139
 biopsy, 137–139
 fine needle aspiration, 136–138
 in elderly, special problems in, 150, 154–155
 incidence of, 131–132
 localized, management of, 143–147
 radiation therapy, 145–148
 radical prostatectomy, 143–145
 surgical treatment of, 626–627
 metastatic, treatment of, 148–150
 natural history of, 132–134
 pathology of, 134
 radiation therapy for, 145–147
 staging of, 139–143
 bone scanning for, 143
 computed tomography for, 141
 digital rectal examination for, 139–140
 magnetic resonance imaging for, 141–142
 pelvic lymphadenectomy for, 142
 prostate specific antigen for, 142–143
 systems for, 136
 transrectal ultrasonography for, 140–141
 treatment of, patient's philosophy in, 154
 tumors in, progression of, 134–135
 Prostate specific antigen, for prostate cancer staging, 142–143
 Prostatectomy, for benign prostatic hyperplasia, 620–622
 indications for, 615
 radical, for prostate cancer, 144–145, 627
 Prosthetic balloon dilatation, for urinary incontinence, 64
 Prostatic oncology, 131–161. See also *Prostate cancer*.
 Prostatism, differential diagnosis of, 612
 Prosthetic heart valve, in surgical patient, anticoagulation for, 521
 Protein, dietary, in diabetics, 893
 Protein binding, of drugs, in perioperative patient, 544
 Protein status, in diabetics, 884
 Proteinuria, in diabetics, 814–816

Pseudomembranous colitis, drug-induced, alternative drugs for, 428-429
Pseudoobstruction, colonic, surgery for, 603
Psoriasis, 213-214
Psychiatric considerations, perioperative, 543-556
Psychiatric medications, and diabetes-related impotence, 778-779
Psychological counseling, for diabetes-related impotence, 790
in home health care, 945
Psychological problems, in male diabetics, and sexual dysfunction, 774
postoperative, effect on discharge, 678-679
Psychotropics, alternatives to, 432
Pulmonary edema, in surgical patient, 522
Pulmonary embolism, atypical/nonspecific presentation of, 726
in hip surgery, 580
postoperative, effect on discharge, 679
risk of, 533
prophylaxis for, in surgical patient, 531-542
modalities of, 533-536
risk factor assessment in, 532-533
Pulmonary function testing, postoperative, effect on discharge, 677
Pyridoxine, in diabetics, 889-890

Quality of life, definition of, 309
drug treatment and, in elderly, 309-317
in diabetes mellitus, 863-882
measurement of, 310-312

Race, in United States population, 4
Radiation therapy, for prostate cancer, 145-148
complications of, 147
interstitial, 146
Radionuclide imaging, of diabetic foot osteomyelitis, 758-759
Rand Short-Form Health survey, for diabetics, 870-871
Randomized clinical trial. See *Drug trials, clinical*.
Reaction time, in diabetics, 735
Recall, in diabetics, 736
Receptor sensitivity, of drugs, in perioperative patient, 544
Recognition, in diabetics, 736
Rectal examination, digital, for prostate cancer staging, 139-140
in urinary dysfunction, 34
Rehabilitation, of postoperative patient, 679-681

Renal. See also *Kidney(s)*.
Renal artery stenosis, 14-15
Renal calculus disease, 115-129. See also *Urolithiasis*.
Renal excretion, of drugs, in perioperative patient, 544
Renal failure, acute, 25-27
identifying mechanism of, 23-24
in surgical illness, 560-562
intraoperative management of, 565-566
nonoliguric, 25
treatment of, 26-27
chronic, and sexual dysfunction, 193
drug doses in, formulas for, 28-29
Renal function, disorders of, in diabetics, 807-825
clinical and public health impact of, 807-808
incidence vs prevalence of, 809
methodologic issues in, 808-810
in surgical patient, prevention and management of, 564-567
neurohumoral control of, 20
perioperative management of, 557-569
postoperative support of, 566-567
preoperative evaluation of, 564-565
with urinary tract replacement, 16-18
Renal physiology, changes with aging, 557-560
Renal tubular acidosis, 21-22
and urolithiasis, 118
Reproductive system, normal age-related physiologic changes in, 724
Reserpine, for hypertension, 430
Residual urine, increased, as indication for prostatectomy, 616
with intermittent self-catheterization, 105-106
Respiratory system, age-prevalent disease of, 725
age-related physiologic changes in, 723
Retinal artery occlusion, central, arteriosclerosis and, 665
Retinal detachment surgery, risk with, 662
Retinopathy, in diabetics. See *Diabetic retinopathy*.
Retromolar trigone, squamous cell cancer of, mandibular splitting surgery for, 644
Richards compression screw, for femoral neck fracture, 573, 575
for intertrochanteric fracture, 578
Risk, assessment of, in surgical decision-making, 470-471
surgical, anesthesia-related, 463
patient-related, 464-465
procedure-related, 464
Risk/benefit ratio, in clinical drug trials, 239-240
Roentgenography, of diabetic foot osteomyelitis, 757

Salicylates, 380–385
 absorption of, 381–382
 distribution of, 382
 elimination of, 384–385
 metabolism of, 382–384

Saskatchewan Short Mental Status Questionnaire, 471

Scabies, 210–212

Scintigraphy, of diabetic foot osteomyelitis, 757–758

Sedation, with neuroleptics, 412

Sedatives, alternatives to, 434–435
 in geriatric patients, 502–503

Selenium, in diabetics, 887

Self-catheterization, intermittent, 101–107.
 See also *Intermittent self-catheterization*.

Semantic memory, in elderly diabetics, 737

Sensorcaine, for local anesthesia, 88

Sensory system, normal age-related physiologic changes in, 724

Sepsis, surgically related, prevention of, 476–477

Sex ratio, in United States, 2–4

Sex therapy, for diabetes-related impotence, 790

Sexual activity, male, normal age-related changes in, 773–774
 with hypertension drug treatment, 315

Sexual dysfunction, in diabetics, 878
 male, organic causes of, 774–779
 psychogenic causes of, 774

in elderly men, 185–196
 iatrogenic causes of, 192–193
 medical causes of, 188–190
 medication-induced, 190–192
 treatment of, 193–195
 with diabetes mellitus, 774–779, 878

in elderly women, 197–203
 iatrogenic causes of, 201
 illnesses causing, 200–201
 medication-induced, 201
 with diabetes mellitus, 878

Sexual excitation, in male diabetics, 772–773

Sexual function, age-related physiologic changes in, 186–188

Shock, with transurethral resection of prostate, 619

Sinus node function, impaired, in surgical patient, 523–524

Skin, concerns with, in surgical patient, 500–501
 home care of, for diabetics, 948–949
 infections of, in foot, in diabetics, 750–756
 lesions of, excision of, planning for, 637
 normal age-related physiologic changes in, 724

Skin flap, for wound closure, 635–636

Skin graft, for wound closure, 635

Skin tumor, local flap for, 637

plastic surgery for, 636–639

Small intestine, surgery on, 598–601
 for obstruction, 598–599

Smell, normal age-related physiologic changes in, 724

Smoking cessation, for diabetes-related impotence, 786

Social function, limitations of, in diabetics, 868, 879

Sodium, homeostasis of, changes with aging, 559
 tubular reabsorption of, defective, 23–24

Soft tissue infections, of foot, in diabetics, 750–756

Somatosensory-evoked potential testing, in diabetes-related erectile dysfunction, 781–782

Speech/language therapist, in home health care team, 945

Spermatic cord block, with local anesthesia, 88–89

Spermatocoection, local anesthesia for, 97–98

Sphincterotomy, endoscopic, for biliary stone disease, in high-risk elderly, 484

Spinal cord, normal age-related physiologic changes in, 723

Splenchnectomy, for pancreatic carcinoma, 598

Sternum, unstable, plastic surgery for, 646

Steroids, 359

Stomach, surgery on, 590–593

Stress incontinence, urge incontinence vs, 63

Stress ulcer, surgically related, prevention of, 477

Stroke. See *Cerebrovascular accidents*.

Sublimaze, with local anesthesia, 87

Sulfonylurea agents, clinical use of, 910–917
 for older diabetics, 699, 903–921
 insulin with, 915–917, 928
 selection of, 914–915
 history of, 903–904
 hypoglycemia with, 909–910
 initial doses of, 912
 mechanism of action of, 904–905
 pharmacology of, 905
 side effects of, 905–908
 University Group Diabetes Program study of, 908

Sulindac, 388

Supraventricular arrhythmia, in surgical patient, 523

Surgeon, perioperative responsibilities of, 469–480

Surgery, choosing site of, 493–497
 complications in, prevention of, 476–477
 decision for, 470–471
 importance of, relationship to physiologic age, 460

in diabetics, for bone infections, 760
for foot infections, 755-756
in high-risk elderly, alternatives to, 481-492

intraoperative technique in, 473-474
open, local anesthesia for, 94-98
perioperative drug therapy in, 474-475
positioning in, in geriatric patients, 500-501

postoperative care in, 474
preoperative measures in, 471-473
renal response to, 560
risk of, considerations in, 464, 660

Surgical illness, renal-electrolyte risks of, 560-564

Surgical patient, discharge planning for, 669-683. See also *Discharge planning*
elderly, environmental and equipment needs of, 675
in-home care of, postoperative, 679
initial interview with, 469-470
rehabilitation of, 669-683

Sympathomimetics, for diabetes-related retrograde ejaculation, 787

Syndrome of inappropriate antidiuretic hormone secretion, with sulfonylureas, 907

Syphilis, 208-209

Tardive dyskinesia, with neuroleptics, 412

Taste, normal age-related physiologic changes in, 724

Terazosin, for benign prostatic hypertrophy, 75

Testosterone, decrease in, with aging, 186
for diabetes-related impotence, 786

Theophylline, for bronchodilation, 425-426

Thermoregulation, alterations in, 273
in diabetics, 698

Thiamine, in diabetics, 889

Thiazide diuretics, for hypertension, 336

Thioridazine, for dementia, review of literature on, 415

Thiothixine, for dementia, review of literature on, 415

Thromboembolism, surgically related, prevention of, 477

Thrombosis, deep vein, prophylaxis for, in surgical patient, 531-542. See also *Deep vein thrombosis*.

Tissue flap, definition of, 635

Tobacco use, and sexual dysfunction, 192

Tolazamide, for diabetes mellitus, initial doses of, 912
properties of, 905-906

Tolbutamide, for older diabetics, 915
initial doses of, 912
properties of, 905-906

Trace element status, in diabetics, 885

Tranquilizers, and sexual dysfunction, 191

Transient ischemic attacks, atypical/nonspecific presentation of, 726

Transitional cell carcinoma, of upper urinary tract, 163-171. See also *Upper urinary tract*

Transrectal ultrasonography, for prostate cancer staging, 140-141

Transurethral balloon dilatation of prostate, for benign prostatic hypertrophy, 78-80

Transurethral resection of prostate, and sexual dysfunction, 192

anesthesia for, local, 93, 94
anesthetic problems in, 508
evaluation for, 80-82
for benign prostatic hyperplasia (hypertrophy), 77-78, 618-620
indications for, 73
surgical alternatives to, 77-80

Treatment failure, drug, definition of, 296

Tricyclic antidepressants, 357-358
and sexual dysfunction, 191
perioperative use of, 550

Trifluoperazine, for dementia, review of literature on, 414

Triglyceride levels, and cognitive function, in diabetics, 741-742

Trunk, plastic surgery of, 645-652

Tubular function, impaired, 21-25
defective calcium reabsorption in, 22-23
defective hydrogen ion secretion in, 21-22
defective phosphate reabsorption in, 22-23
defective sodium reabsorption in, 23-24

Tubular injury, and acute renal failure, 25

Tubular necrosis, acute. See *Acute tubular necrosis*.

Tumor resection, percutaneous, for upper urinary tract transitional cell carcinoma, 165-167

Ultrasoundography, of diabetic foot osteomyelitis, 758

United States population, age profile of, 3-4
ethnic origin of, 4
geographic distribution of, 4-5
life expectancy of, 1-2
living arrangements of, 5-6
marital status of, 5
population growth in, 1900-2030, 2
racial characteristics of, 4
sex ratio in, 2-4

University Group Diabetes Program study, of sulfonylureas, 908, 927, 935

Upper urinary tract, transitional cell carcinoma of, combination therapy for, 166

Upper urinary tract (Continued)

- conservative management of, 163-171
- intravenous pyelogram of, 167
- local tumor excision in, 163-164
- percutaneous resection of, 164-167
 - follow-up of, 168
 - future goals in, 169-170
 - method of, 165-168
 - results in, 168-169
- recurrences of, 168-169
- supplemental therapy for, 167-168

Urea, clearance of, decreased, with nephron reduction, 20

concentration of, increase in, with altered glomerular filtration rate, 16

reabsorption of, with urinary tract replacement, 18

Ureteroscopy, for urolithiasis, 122-123

Urethral block, local anesthesia for, 92

Urethral dilatation, local anesthesia for, 91-92

Urethral profilometry, in urinary dysfunction, 37-38

Urethral stricture disease, following transurethral resection of prostate, 81

Urethropexy, for stress incontinence, 63

Urethrotomy, internal, local anesthesia for, 91-92

Urinalysis, in urolithiasis, 121

Urinary calculi, 115-129. See also *Urolithiasis*.

- Urinary dysfunction, effects of dominance on, 65-66
- following cerebrovascular accidents, 57-60
- in elderly, assessment of, 31-41
- Urinary flow, impaired, history of, 33-34
- Urinary frequency, following cerebrovascular accidents, 58
- history of, 33
- in benign prostatic hypertrophy, 72

Urinary function, history of, 32-34

Urinary incontinence, and urinary tract infection, 47

- assistive devices for, 952
- drug-induced, 61
- economic impact of, 8-11
- following cerebrovascular accidents, 58-60
 - evaluation of, 60-61
 - treatment of, 61-64
 - in men, 61-63
 - in women, 63-64
- following transurethral resection of prostate, 81
- history of, 33
- in diabetics, 879
- management of, implants in, 112-113
 - nonoperative, 64, 110-111
- overflow, in benign prostatic hypertrophy, 72
- prevalence of, 8
- with radical prostatectomy, 145

Urinary retention, as indication for prostatectomy, 616

drug-induced, 61

in hip surgery, 581

Urinary tract, infection of. See *Urinary tract infection*.

lower, dysfunction of, endourologic management of, 109-113

upper. See *Upper urinary tract*.

Urinary tract infection, 43-53

- atypical/nonspecific presentation of, 726
- definition of, 44
- diagnosis of, 47-48
- epidemiology of, 43-44
- evaluation of, 48
- in hip surgery, 581
- incidence of, 43-44
- management of, 48-50
- microbiology of, 45
- pathogenesis of, 46-47
- perinephric abscess in, 50-51
- postoperative, effect on discharge, 679
- surgically related, prevention of, 477
- symptoms of, 45

Urination, postoperative, effect on discharge, 678

Urine, alkalinization of, for renal calculus disease, 127

Urine volume, increase in, for renal calculus disease, 127

Urodynamic parameters, 65

Urodynamic testing, in prostate evaluation, 614

- in urinary dysfunction, 35-39
- in urinary incontinence, following cerebrovascular accidents, 61

Uroflowmetry, in urinary dysfunction, 36

Urography, intravenous, in urolithiasis, 121

Urolithiasis, 115-129

- diagnostic studies of, 120-121
- etiology of, 115-119
- evaluation of, routine chemistries for, 127
- hypercalciuria in, 116
- in high-risk elderly, alternatives to surgery for, 482-483, 486-487
- inhibition of, 128
- lithotripsy for, 122-125
- medical management of, 126-128
- percutaneous endoscopy for, 123-125
- spontaneous stone passage in, 121
- stone composition in, 116
- symptoms of, 119-120
- treatment of, 121-126
- uroscopy for, 122-123

Urologic dermatology, geriatric, 205-219

- biopsy in, 217-219

Urologic evaluation, diagnostic tests in, 32

Urologic surgery, local anesthesia for, 85-99

- thromboembolism in, prophylaxis for, 537-538

Urosepsis, with intermittent self-catheterization, 106
Uveitis, sarcoidosis and, 665

Vacuum tumescence devices, external, for impotence, 194, 788
Valvular heart disease, in surgical patient, 519-521
Vancomycin, for pseudomembranous colitis, 428
Vascular access, in surgical patient, 500
Vascular function, abnormalities of, and diabetes-related impotence, 775-776
changes in, with aging and hypertension, 286
evaluation of, in diabetes-related erectile dysfunction, 783-784
Vascular injury, and acute renal failure, 25
Vasocongestion, reduced, with aging, 187
Vasodilators, arteriolar, for hypertension, 339-340
investigation of, in quality-of-life assessment, 314
Ventricular arrhythmia, in surgical patient, 523
Ventricular premature contractions, perioperative risk of, 515
Verapamil, for hypertension, 340
Verrucous carcinoma, 216
Versed, with local anesthesia, 86
Videourodynamics, in urinary dysfunction, 38-39
Viral warts, 210
Visual acuity, in diabetics, insulin use and, 833
Visual impairment, in diabetics, 827-837, 875, 877
agency referral for, 951
implications of, 832-835
incidence of, 832-835
prevalence of, 827-832

Visual perception, in diabetics, 735
Visual sexual stimulation, testing of, in diabetes-related erectile dysfunction, 781
Vitamin(s), in diabetics, 888-891
recommended dietary allowances for, in elderly, 894
Vocabulary level, in elderly diabetics, 737
Volume of distribution, definition of, 258
Volvulus, colon, surgery for, 602-603
gastric, surgery for, 592-593

Warfarin, thromboembolism prophylaxis with, 534-535
Warts, viral, 210
Water metabolism, disorders of, 562-563
homeostasis of, changes with aging, 558-559
Weight loss, in diabetics, 891-892
Women, elderly, frequency of coitus in, 199-200
sexual dysfunction in, 197-203
structural changes in, 198
hormonal changes in, 199
normal aging in, 199
Wound healing, impaired, and foot ulcers, in diabetics, 749
Wound infection, in hip surgery, 582

Xylocaine, for local anesthesia, 87-88

Yeast infection, urologic, 206-208
Yohimbine, for diabetes-related impotence, 787

Zinc, in diabetics, 698, 885-886